The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling

Most patients with multiple myeloma treated with current therapies, including immunomodulatory drugs, eventually develop relapsed/refractory disease. Clinical activity of lenalidomide relies on degradation of Ikaros and the consequent reduction in IRF4 expression, both required for myeloma cell surv...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Haematologica
Autori principali: Díaz, Tania, Rodríguez, Vanina, Lozano, Ester, Mena, Mari-Pau, Calderón, Marcos, Rosiñol, Laura, Martínez, Antonio, Tovar, Natalia, Pérez-Galán, Patricia, Bladé, Joan, Roué, Gaël, de Larrea, Carlos Fernández
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ferrata Storti Foundation 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5622862/
https://ncbi.nlm.nih.gov/pubmed/28751557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.164632
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi